Lebrikizumab
- Generic Name
- Lebrikizumab
- Brand Names
- Ebglyss
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 953400-68-5
- Unique Ingredient Identifier
- U9JLP7V031
- Background
Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Phase 3
Recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 430
- Registration Number
- NCT06280716
- Locations
- 🇨🇳
Wannan Medical College Yijishan Hospital, Wuhu, Anhui, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath